CoChat

Association of wearable device-measured vigorous intermittent lifestyle physical activity with mortality

Open access
Stamatakis, Emmanuel, Ahmadi, Matthew N., Gill, Jason M. R., Thøgersen-Ntoumani, Cecilie, Gibala, Martin J., Doherty, Aiden, Hamer, Mark · 2022 · Nature Medicine

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index; 23 of the 59 sources its claims cite were checked for support.

Abstract

Wearable devices can capture unexplored movement patterns such as brief bursts of vigorous intermittent lifestyle physical activity (VILPA) that is embedded into everyday life, rather than being done as leisure time exercise. Here, we examined the association of VILPA with all-cause, cardiovascular disease (CVD) and cancer mortality in 25,241 nonexercisers (mean age 61.8 years, 14,178 women/11,063 men) in the UK Biobank. Over an average follow-up of 6.9 years, during which 852 deaths occurred, VILPA was inversely associated with all three of these outcomes in a near-linear fashion. Compared with participants who engaged in no VILPA, participants who engaged in VILPA at the sample median VILPA frequency of 3 length-standardized bouts per day (lasting 1 or 2 min each) showed a 38%–40% reduction in all-cause and cancer mortality risk and a 48%–49% reduction in CVD mortality risk. Moreover, the sample median VILPA duration of 4.4 min per day was associated with a 26%–30% reduction in all-cause and cancer mortality risk and a 32%–34% reduction in CVD mortality risk. We obtained similar results when repeating the above analyses for vigorous physical activity (VPA) in 62,344 UK Biobank participants who exercised (1,552 deaths, 35,290 women/27,054 men). These results indicate that small amounts of vigorous nonexercise physical activity are associated with substantially lower mortality. VILPA in nonexercisers appears to elicit similar effects to VPA in exercisers, suggesting that VILPA may be a suitable physical activity target, especially in people not able or willing to exercise.

Overview

CoChat Summary

TL;DR

In UK Biobank nonexercisers with wrist-worn accelerometry, brief vigorous intermittent lifestyle physical activity (VILPA) was associated with lower all-cause, cardiovascular disease, and cancer mortality in near-linear dose–response patterns. VILPA in nonexercisers showed associations of similar magnitude to vigorous physical activity (VPA) in exercisers.

Key findings

  • Among 25,241 nonexercisers (mean age 61.8 years; 14,178 women/11,063 men), over mean 6.9 years and 852 deaths, VILPA was inversely associated with all-cause, CVD, and cancer mortality in a near-linear fashion.
  • Median VILPA frequency of 3 length-standardized bouts per day (1 or 2 min each) was associated with 38%–40% lower all-cause and cancer mortality risk and 48%–49% lower CVD mortality risk versus no VILPA.
  • Median VILPA duration of 4.4 min per day was associated with 26%–30% lower all-cause and cancer mortality risk and 32%–34% lower CVD mortality risk.
  • Minimum VILPA doses of 3.4–4.1 min per day were associated with 22%–28% lower mortality risk; fewer than two VILPA bouts per day were associated with 24%–26% lower all-cause and cancer mortality and 33% lower CVD mortality. In 62,344 exercisers (1,552 deaths), context-agnostic VPA showed similar dose–response associations.

Methods

  • Prospective cohort analysis within the UK Biobank accelerometry substudy; nonexercisers reported no leisure-time exercise and no more than one recreational walk per week, while exercisers reported any leisure-time exercise or more than one recreational walk per week.
  • Physical activity intensity was classified from wrist-worn accelerometer data using a previously validated random forest classifier; VILPA bouts were defined as brief nonexercise vigorous-intensity bouts lasting up to 1 or up to 2 min, with length-standardized frequency measures.
  • Cox proportional hazards and Fine–Gray subdistribution hazards models estimated dose–response associations with all-cause, CVD, and cancer mortality, adjusted for age, sex, light and moderate activity, longer VPA bouts, smoking, alcohol, sleep, diet, education, parental history, medication use, and prevalent disease.

Limitations

  • The paper states reverse causation cannot be entirely ruled out, though sensitivity analyses excluding poor self-rated health and events in the first 2 years did not appreciably change results.
  • The paper notes some VILPA activities (for example, carrying heavy shopping bags) may not be perfectly captured by wrist-worn accelerometers, likely leading to random measurement error and underestimation of true associations.
  • The paper states a median 5.5-year lag between baseline covariate measurement and accelerometry, possible measurement error in self-reported exercise/recreational walking used for sample selection, and low UK Biobank response rate (5.5%) with limited representativeness; it also notes data sparsity and few events at higher VILPA energy expenditure levels made between-strata comparisons less conclusive.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41591-022-02100-x

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Flow diagram of non-exercisers. Flow diagram of UK Biobank participants for the dose–response analyses of VILPA.
Fig. 1 Flow diagram of non-exercisers. Flow diagram of UK Biobank participants for the dose–response analyses of VILPA.CC BY · PubMed Central
Fig. 2 Association of the daily duration and frequency of VILPA with all-cause mortality. a,b, Dose–response curves showing all-cause mortality HR associated with increasing daily duration of VILPA, for bouts of VILPA up to 1 min (a) and 2 min (b) in duration. c,d, Dose–response curves showing all-cause mortality HR associated with increasing daily frequency of VILPA, for length-standardized bouts of VILPA 1 min (c) and 2 min (d) in duration. Data are shown for n = 25,241 participants with 852 events and with a mean follow-up of 6.9 (0.8) years. Diamond, minimal dose, as indicated by the ED50 statistic which estimates the daily duration/frequency of VILPA associated with 50% of optimal risk reduction. Circle, HR associated with the median VILPA value (see Supplementary Table 4 for the list of values). Data are adjusted for the covariates listed in the online Methods. The shaded region demarcated by dashed lines represents the 95% CI. The solid line that lies within the shaded region represents the HR. The arrowhead represents the absence of an observed inflection point (for example, larger risk reduction with higher amounts of VILPA). The histogram on the right shows the sample distribution.
Fig. 2 Association of the daily duration and frequency of VILPA with all-cause mortality. a,b, Dose–response curves showing all-cause mortality HR associated with increasing daily duration of VILPA, for bouts of VILPA up to 1 min (a) and 2 min (b) in duration. c,d, Dose–response curves showing all-cause mortality HR associated with increasing daily frequency of VILPA, for length-standardized bouts of VILPA 1 min (c) and 2 min (d) in duration. Data are shown for n = 25,241 participants with 852 events and with a mean follow-up of 6.9 (0.8) years. Diamond, minimal dose, as indicated by the ED50 statistic which estimates the daily duration/frequency of VILPA associated with 50% of optimal risk reduction. Circle, HR associated with the median VILPA value (see Supplementary Table 4 for the list of values). Data are adjusted for the covariates listed in the online Methods. The shaded region demarcated by dashed lines represents the 95% CI. The solid line that lies within the shaded region represents the HR. The arrowhead represents the absence of an observed inflection point (for example, larger risk reduction with higher amounts of VILPA). The histogram on the right shows the sample distribution.CC BY · PubMed Central
Fig. 3 Association of the daily duration and frequency of VILPA with CVD mortality. a,b, Dose–response curves showing CVD mortality HRs associated with increasing daily duration of VILPA, for bouts of VILPA up to 1 min (a) and 2 min (b) in duration. c,d, Dose–response curves showing CVD mortality HRs associated with increasing daily frequency of VILPA, for length-standardized bouts of VILPA1 min (c) and 2 min (d) in duration. Data are shown for n = 23,903 participants with 266 events and with a mean follow-up of 6.9 (0.8) years. Diamond, minimal dose, as indicated by the ED50 statistic which estimates the daily duration/frequency of VILPA associated with 50% of optimal risk reduction. Circle, HR associated with the median VILPA value (see Supplementary Table 4 for the list of values). Data are adjusted for the covariates listed in the online Methods. The shaded region demarcated by dashed lines represents the 95% CI. The solid line that lies within the shaded region represents the HR. The arrowhead represents the absence of an observed inflection point (for example, larger risk reduction with higher amounts of VILPA). The histogram on the right shows the sample distribution.
Fig. 3 Association of the daily duration and frequency of VILPA with CVD mortality. a,b, Dose–response curves showing CVD mortality HRs associated with increasing daily duration of VILPA, for bouts of VILPA up to 1 min (a) and 2 min (b) in duration. c,d, Dose–response curves showing CVD mortality HRs associated with increasing daily frequency of VILPA, for length-standardized bouts of VILPA1 min (c) and 2 min (d) in duration. Data are shown for n = 23,903 participants with 266 events and with a mean follow-up of 6.9 (0.8) years. Diamond, minimal dose, as indicated by the ED50 statistic which estimates the daily duration/frequency of VILPA associated with 50% of optimal risk reduction. Circle, HR associated with the median VILPA value (see Supplementary Table 4 for the list of values). Data are adjusted for the covariates listed in the online Methods. The shaded region demarcated by dashed lines represents the 95% CI. The solid line that lies within the shaded region represents the HR. The arrowhead represents the absence of an observed inflection point (for example, larger risk reduction with higher amounts of VILPA). The histogram on the right shows the sample distribution.CC BY · PubMed Central
Fig. 4 Association of the daily duration and frequency of VILPA with cancer mortality. a,b, Dose–response curves showing cancer mortality HRs associated with increasing daily duration of VILPA, for bouts of VILPA up to 1 min (a) and 2 min (b) in duration. c,d, Dose–response curves showing cancer mortality HRs associated with increasing daily frequency of VILPA, for length-standardized bouts of VILPA 1 min (c) and 2 min (d) in duration. Data are shown for n = 22,966 participants with 511 events and with a mean follow-up of 6.9 (0.8) years. Diamond, minimal dose, as indicated by the ED50 statistic which estimates the daily duration/frequency of VILPA associated with 50% of optimal risk reduction. Circle, HR associated with the median VILPA value (see Supplementary Table 4 for the list of values). Data are adjusted for the covariates listed in the online Methods. The shaded region demarcated by dashed lines represents the 95% CI. The solid line that lies within the shaded region represents the HR. The arrowhead represents the absence of an observed inflection point (for example, larger risk reduction with higher amounts of VILPA). The histogram on the right shows the sample distribution.
Fig. 4 Association of the daily duration and frequency of VILPA with cancer mortality. a,b, Dose–response curves showing cancer mortality HRs associated with increasing daily duration of VILPA, for bouts of VILPA up to 1 min (a) and 2 min (b) in duration. c,d, Dose–response curves showing cancer mortality HRs associated with increasing daily frequency of VILPA, for length-standardized bouts of VILPA 1 min (c) and 2 min (d) in duration. Data are shown for n = 22,966 participants with 511 events and with a mean follow-up of 6.9 (0.8) years. Diamond, minimal dose, as indicated by the ED50 statistic which estimates the daily duration/frequency of VILPA associated with 50% of optimal risk reduction. Circle, HR associated with the median VILPA value (see Supplementary Table 4 for the list of values). Data are adjusted for the covariates listed in the online Methods. The shaded region demarcated by dashed lines represents the 95% CI. The solid line that lies within the shaded region represents the HR. The arrowhead represents the absence of an observed inflection point (for example, larger risk reduction with higher amounts of VILPA). The histogram on the right shows the sample distribution.CC BY · PubMed Central
Extended Data Fig. 1 All-cause mortality dose-response of VILPA frequency and duration with adjustment for body mass index and exclusion of poor health. Frequency of length-standardized VILPA bouts up to 2 minutes (A) and Duration of VILPA from bouts up to 2 minutes (B). Diamond: the minimal dose, as indicated by the ED50 statistic which estimates the daily duration/frequency of VILPA associated with 50% of optimal risk reduction. Circle: the hazard ratio associated with the median VILPA value. Analyses adjusted for age, sex, duration of light intensity physical activity, duration of moderate intensity physical activity, smoking history, alcohol consumption, accelerometer estimated sleep duration, fruit and vegetable consumption, education, self-reported parental history of cardiovascular disease and cancer, and self-reported medication use (cholesterol, blood pressure, and diabetes), and prevalent cancer and CVD. All analyses were additionally adjusted for vigorous physical activity bouts (VILPA frequency analyses) or vigorous physical activity duration (VILPA duration analyses) coming from bouts lasting more than two minutes. Models are sequentially adjusted for: (1) body mass index; (2) exclusion of participants who were underweight (<18.5 kg/m2 or self-reported poor health). See Online Methods for further details on the statistical methodology. Shaded region with dashed lines represents 95%CI. Solid line represents point estimate. Arrow represents no inflection point.
Extended Data Fig. 1 All-cause mortality dose-response of VILPA frequency and duration with adjustment for body mass index and exclusion of poor health. Frequency of length-standardized VILPA bouts up to 2 minutes (A) and Duration of VILPA from bouts up to 2 minutes (B). Diamond: the minimal dose, as indicated by the ED50 statistic which estimates the daily duration/frequency of VILPA associated with 50% of optimal risk reduction. Circle: the hazard ratio associated with the median VILPA value. Analyses adjusted for age, sex, duration of light intensity physical activity, duration of moderate intensity physical activity, smoking history, alcohol consumption, accelerometer estimated sleep duration, fruit and vegetable consumption, education, self-reported parental history of cardiovascular disease and cancer, and self-reported medication use (cholesterol, blood pressure, and diabetes), and prevalent cancer and CVD. All analyses were additionally adjusted for vigorous physical activity bouts (VILPA frequency analyses) or vigorous physical activity duration (VILPA duration analyses) coming from bouts lasting more than two minutes. Models are sequentially adjusted for: (1) body mass index; (2) exclusion of participants who were underweight (<18.5 kg/m2 or self-reported poor health). See Online Methods for further details on the statistical methodology. Shaded region with dashed lines represents 95%CI. Solid line represents point estimate. Arrow represents no inflection point.CC BY · PubMed Central
Extended Data Fig. 2 Cardiovascular disease mortality dose-response of VILPA frequency and duration with adjustment for body mass index and exclusion of poor health. Frequency of length-standardized VILPA bouts up to 2 minutes (A) and Duration of VILPA from bouts up to 2 minutes (B). Diamond: the minimal dose, as indicated by the ED50 statistic which estimates the daily duration/frequency of VILPA associated with 50% of optimal risk reduction. Circle: the hazard ratio associated with the median VILPA value. Analyses adjusted for age, sex, duration of light intensity physical activity, duration of moderate intensity physical activity, smoking history, alcohol consumption, accelerometer estimated sleep duration, fruit and vegetable consumption, education, self-reported parental history of cardiovascular disease and cancer, and self-reported medication use (cholesterol, blood pressure, and diabetes). All analyses were additionally adjusted for vigorous physical activity bouts (VILPA frequency analyses) or vigorous physical activity duration (VILPA duration analyses) coming from bouts lasting more than two minutes. Models are sequentially adjusted for: (1) body mass index; (2) exclusion of participants who were underweight (<18.5 kg/m2 or self-reported poor health). See Online Methods for further details on the statistical methodology. Shaded region with dashed lines represents 95%CI. Solid line represents point estimate. Arrow represents no inflection point.
Extended Data Fig. 2 Cardiovascular disease mortality dose-response of VILPA frequency and duration with adjustment for body mass index and exclusion of poor health. Frequency of length-standardized VILPA bouts up to 2 minutes (A) and Duration of VILPA from bouts up to 2 minutes (B). Diamond: the minimal dose, as indicated by the ED50 statistic which estimates the daily duration/frequency of VILPA associated with 50% of optimal risk reduction. Circle: the hazard ratio associated with the median VILPA value. Analyses adjusted for age, sex, duration of light intensity physical activity, duration of moderate intensity physical activity, smoking history, alcohol consumption, accelerometer estimated sleep duration, fruit and vegetable consumption, education, self-reported parental history of cardiovascular disease and cancer, and self-reported medication use (cholesterol, blood pressure, and diabetes). All analyses were additionally adjusted for vigorous physical activity bouts (VILPA frequency analyses) or vigorous physical activity duration (VILPA duration analyses) coming from bouts lasting more than two minutes. Models are sequentially adjusted for: (1) body mass index; (2) exclusion of participants who were underweight (<18.5 kg/m2 or self-reported poor health). See Online Methods for further details on the statistical methodology. Shaded region with dashed lines represents 95%CI. Solid line represents point estimate. Arrow represents no inflection point.CC BY · PubMed Central
Extended Data Fig. 3 Cancer mortality dose-response of VILPA duration and frequency with adjustment for body mass index and exclusion of poor health. Frequency of length-standardized VILPA bouts up to 2 minutes (A) and Duration of VILPA from bouts up to 2 minutes (B). Diamond: the minimal dose, as indicated by the ED50 statistic which estimates the daily duration/frequency of VILPA associated with 50% of optimal risk reduction. Circle: the hazard ratio associated with the median VILPA value. Analyses adjusted for age, sex, duration of light intensity physical activity, duration of moderate intensity physical activity, smoking history, alcohol consumption, accelerometer estimated sleep duration, fruit and vegetable consumption, education, self-reported parental history of cardiovascular disease and cancer, and self-reported medication use (cholesterol, blood pressure, and diabetes). All analyses were additionally adjusted for vigorous physical activity bouts (VILPA frequency analyses) or vigorous physical activity duration (VILPA duration analyses) coming from bouts lasting more than two minutes. Models were sequentially adjusted for: (1) body mass index; (2) exclusion of participants who were underweight (<18.5 kg/m2 or self-reported poor health). See Online Methods for further details on the statistical methodology. Shaded region with dashed lines represents 95%CI. Solid line represents point estimate. Arrow represents no inflection point.
Extended Data Fig. 3 Cancer mortality dose-response of VILPA duration and frequency with adjustment for body mass index and exclusion of poor health. Frequency of length-standardized VILPA bouts up to 2 minutes (A) and Duration of VILPA from bouts up to 2 minutes (B). Diamond: the minimal dose, as indicated by the ED50 statistic which estimates the daily duration/frequency of VILPA associated with 50% of optimal risk reduction. Circle: the hazard ratio associated with the median VILPA value. Analyses adjusted for age, sex, duration of light intensity physical activity, duration of moderate intensity physical activity, smoking history, alcohol consumption, accelerometer estimated sleep duration, fruit and vegetable consumption, education, self-reported parental history of cardiovascular disease and cancer, and self-reported medication use (cholesterol, blood pressure, and diabetes). All analyses were additionally adjusted for vigorous physical activity bouts (VILPA frequency analyses) or vigorous physical activity duration (VILPA duration analyses) coming from bouts lasting more than two minutes. Models were sequentially adjusted for: (1) body mass index; (2) exclusion of participants who were underweight (<18.5 kg/m2 or self-reported poor health). See Online Methods for further details on the statistical methodology. Shaded region with dashed lines represents 95%CI. Solid line represents point estimate. Arrow represents no inflection point.CC BY · PubMed Central
Extended Data Fig. 4 Dose-response association of categorised Vigorous Intermittent Lifestyle Physical Activity (VILPA) duration quarters with all-cause mortality (n = 25,241). Duration of VILPA bout up to 1 minute (A); Duration of VILPA bouts up to 2 minutes (B); Frequency of length-standardized VILPA bouts up to 1 minute (C); and Frequency of length-standardized VILPA bouts up to 2 minutes (D). Participants with no VILPA were the reference category. The remaining categories are based on VILPA tertiles. Analyses adjusted for age, sex, duration of light intensity physical activity, duration of moderate intensity physical activity, smoking history, alcohol consumption, accelerometer estimated sleep duration, fruit and vegetable consumption, education, self-reported parental history of cardiovascular disease and cancer, and self-reported medication use (cholesterol, blood pressure, and diabetes), and prevalent cancer and CVD. All analyses were additionally adjusted for vigorous physical activity duration/bouts lasting more than one/two minutes, as appropriate. See Online Methods for further details on the statistical methodology. Sample size = 25,241; events = 868. Error bars represent 95% CI.
Extended Data Fig. 4 Dose-response association of categorised Vigorous Intermittent Lifestyle Physical Activity (VILPA) duration quarters with all-cause mortality (n = 25,241). Duration of VILPA bout up to 1 minute (A); Duration of VILPA bouts up to 2 minutes (B); Frequency of length-standardized VILPA bouts up to 1 minute (C); and Frequency of length-standardized VILPA bouts up to 2 minutes (D). Participants with no VILPA were the reference category. The remaining categories are based on VILPA tertiles. Analyses adjusted for age, sex, duration of light intensity physical activity, duration of moderate intensity physical activity, smoking history, alcohol consumption, accelerometer estimated sleep duration, fruit and vegetable consumption, education, self-reported parental history of cardiovascular disease and cancer, and self-reported medication use (cholesterol, blood pressure, and diabetes), and prevalent cancer and CVD. All analyses were additionally adjusted for vigorous physical activity duration/bouts lasting more than one/two minutes, as appropriate. See Online Methods for further details on the statistical methodology. Sample size = 25,241; events = 868. Error bars represent 95% CI.CC BY · PubMed Central
Extended Data Fig. 5 Comparison of the dose-response associations of daily duration of vigorous intermittent lifestyle physical activity (non-exercisers) and context-agnostic (that is exercise or non-exercise) vigorous physical activity (exercisers) with mortality (bouts up to 2 minutes). All-cause mortality (A); cardiovascular disease mortality (B); and cancer mortality (C). Exercisers, n = 62,344 were included in the all-cause mortality (1,552 events), n = 56,810 in the CVD mortality (303 events) and n = 56,397 in the cancer mortality analyses (736 events). Non-exercisers n = 25,241 were included in the all-cause mortality analyses (852 events), were included in the all-cause mortality, n = 23,903 in the CVD mortality analyses (266 events), n = 22,966 in the cancer mortality analyses (511 events). Diamond: the minimal dose, as indicated by the ED50 statistic which estimates the daily duration/frequency of VILPA associated with 50% of optimal risk reduction. Circle: the hazard ratio associated with the median VILPA value. See Supplementary Tables 4 (nonexercisers) and 6 (exercisers) for the list of values. Analyses adjusted for age, sex, duration of light intensity physical activity, duration of moderate intensity physical activity, smoking history, alcohol consumption, accelerometer estimated sleep duration, fruit and vegetable consumption, education, self-reported parental history of cardiovascular disease and cancer, and self-reported medication use (cholesterol, blood pressure, and diabetes), and prevalent cancer and CVD (for all-cause mortality). All analyses were additionally adjusted for vigorous physical activity frequency of bouts lasting more than two minutes. See Online Methods for further details on the statistical methodology. Shaded region with dashed lines represents 95%CI. Solid line represents point estimate. Arrow represents no inflection point.
Extended Data Fig. 5 Comparison of the dose-response associations of daily duration of vigorous intermittent lifestyle physical activity (non-exercisers) and context-agnostic (that is exercise or non-exercise) vigorous physical activity (exercisers) with mortality (bouts up to 2 minutes). All-cause mortality (A); cardiovascular disease mortality (B); and cancer mortality (C). Exercisers, n = 62,344 were included in the all-cause mortality (1,552 events), n = 56,810 in the CVD mortality (303 events) and n = 56,397 in the cancer mortality analyses (736 events). Non-exercisers n = 25,241 were included in the all-cause mortality analyses (852 events), were included in the all-cause mortality, n = 23,903 in the CVD mortality analyses (266 events), n = 22,966 in the cancer mortality analyses (511 events). Diamond: the minimal dose, as indicated by the ED50 statistic which estimates the daily duration/frequency of VILPA associated with 50% of optimal risk reduction. Circle: the hazard ratio associated with the median VILPA value. See Supplementary Tables 4 (nonexercisers) and 6 (exercisers) for the list of values. Analyses adjusted for age, sex, duration of light intensity physical activity, duration of moderate intensity physical activity, smoking history, alcohol consumption, accelerometer estimated sleep duration, fruit and vegetable consumption, education, self-reported parental history of cardiovascular disease and cancer, and self-reported medication use (cholesterol, blood pressure, and diabetes), and prevalent cancer and CVD (for all-cause mortality). All analyses were additionally adjusted for vigorous physical activity frequency of bouts lasting more than two minutes. See Online Methods for further details on the statistical methodology. Shaded region with dashed lines represents 95%CI. Solid line represents point estimate. Arrow represents no inflection point.CC BY · PubMed Central
Extended Data Fig. 6 Comparison of the dose-response associations of daily frequency of vigorous intermittent lifestyle physical activity (non-exercisers) and context-agnostic (that is exercise or non-exercise) vigorous physical activity (exercisers) with mortality (length-standardized bouts up to 2 minutes). All-cause mortality (A); cardiovascular disease mortality (B); and cancer mortality (C). Exercisers, n = 62,344 were included in the all-cause mortality (1,552 events), n = 56,810 in the CVD mortality (303 events) and n = 56,397 in the cancer mortality analyses (736 events). Non-exercisers n = 25,241 were included in the all-cause mortality analyses (852 events), were included in the all-cause mortality, n = 23,903 in the CVD mortality analyses (266 events), n = 22,966 in the cancer mortality analyses (511 events). Diamond: the minimal dose, as indicated by the ED50 statistic which estimates the daily duration/frequency of VILPA associated with 50% of optimal risk reduction. Circle: the hazard ratio associated with the median VILPA value. See Supplementary Tables 4 (nonexercisers) and 6 (exercisers) for the list of values. Triangle: optimal dose value defined as the nadir of the curve. Analyses adjusted for age, sex, duration of light intensity physical activity, duration of moderate intensity physical activity, smoking history, alcohol consumption, accelerometer estimated sleep duration, fruit and vegetable consumption, education, self-reported parental history of cardiovascular disease and cancer, and self-reported medication use (cholesterol, blood pressure, and diabetes), and prevalent cancer and CVD (for all-cause mortality). All analyses were additionally adjusted for vigorous physical activity bouts lasting more than two minutes. See Online Methods for further details on the statistical methodology. Shaded region with dashed lines represents 95%CI. Solid line represents point estimate. Arrow represents no inflection point.
Extended Data Fig. 6 Comparison of the dose-response associations of daily frequency of vigorous intermittent lifestyle physical activity (non-exercisers) and context-agnostic (that is exercise or non-exercise) vigorous physical activity (exercisers) with mortality (length-standardized bouts up to 2 minutes). All-cause mortality (A); cardiovascular disease mortality (B); and cancer mortality (C). Exercisers, n = 62,344 were included in the all-cause mortality (1,552 events), n = 56,810 in the CVD mortality (303 events) and n = 56,397 in the cancer mortality analyses (736 events). Non-exercisers n = 25,241 were included in the all-cause mortality analyses (852 events), were included in the all-cause mortality, n = 23,903 in the CVD mortality analyses (266 events), n = 22,966 in the cancer mortality analyses (511 events). Diamond: the minimal dose, as indicated by the ED50 statistic which estimates the daily duration/frequency of VILPA associated with 50% of optimal risk reduction. Circle: the hazard ratio associated with the median VILPA value. See Supplementary Tables 4 (nonexercisers) and 6 (exercisers) for the list of values. Triangle: optimal dose value defined as the nadir of the curve. Analyses adjusted for age, sex, duration of light intensity physical activity, duration of moderate intensity physical activity, smoking history, alcohol consumption, accelerometer estimated sleep duration, fruit and vegetable consumption, education, self-reported parental history of cardiovascular disease and cancer, and self-reported medication use (cholesterol, blood pressure, and diabetes), and prevalent cancer and CVD (for all-cause mortality). All analyses were additionally adjusted for vigorous physical activity bouts lasting more than two minutes. See Online Methods for further details on the statistical methodology. Shaded region with dashed lines represents 95%CI. Solid line represents point estimate. Arrow represents no inflection point.CC BY · PubMed Central

Verification

Claims the paper makes

6 Valid · 1 Not valid · 19 Not checked · 72 Own results and interpretations

39 more claims

Create a free account to see all 98 claims and to verify the 36 references still open.

See all claims — free account
  • It may state two separate claims as one. 31
  • Probably not a substantial claim. 30
  • The quote only partly states this claim. 2
  • Not yet classified. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 53 references

Cited by

See all 384

Metadata

Authors
Stamatakis, E., Ahmadi, M. N., Gill, J. M. R., Thøgersen-Ntoumani, C., Gibala, M. J., Doherty, A., & Hamer, M.
Affiliations
  • The University of Sydney (AU)
  • University of Glasgow (GB)
  • McMaster University (CA)
  • University of Oxford (GB)
  • University College London (GB)
Corresponding author
Stamatakis, Emmanuel
Venue
Nature Medicine
Published
2022-12
Volume
28
Issue
12
Pages
2521-2529
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4311501860
Cited by
336
References
51
Citations by year
2026: 80 · 2025: 77 · 2024: 117 · 2023: 62
FWCI
39.58
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, cc-by)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • Department of Health | National Health and Medical Research Council (APP1180812, APP 1194510)
  • Wellcome Trust (223100/Z/21/Z)
  • British Heart Foundation (RE/18/3/34214)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Physical Activity and Health
  • Health Sciences › Medicine › Physiology (medical) › Cardiovascular and exercise physiology
  • Physical Sciences › Computer Science › Computer Vision and Pattern Recognition › Context-Aware Activity Recognition Systems
Keywords
wearable devices, all-cause mortality, cardiovascular mortality, cancer mortality
MeSH terms
Cardiovascular Diseases, Female, Humans, Leisure Activities, Life Style, Male, Middle Aged, Mortality, Neoplasms, Exercise

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association of wearable device-measured vigorous intermittent lifestyle physical activity with mortality. https://app.cochat.ai/papers/10.1038/s41591-022-02100-x
The paper
Stamatakis, E., Ahmadi, M. N., Gill, J. M. R., Thøgersen-Ntoumani, C., Gibala, M. J., Doherty, A., & Hamer, M. (2022). Association of wearable device-measured vigorous intermittent lifestyle physical activity with mortality. Nature Medicine. https://doi.org/10.1038/s41591-022-02100-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.